Ventyx Biosciences, Inc. (NASDAQ:VTYX) Q2 2022 Earnings Conference Call August 15, 2022 4:30 PM ET

Company Participants

Marty Auster - Chief Financial Officer

Raju Mohan - Founder & Chief Executive Officer

Bill Sandborn - President & Chief Medical Officers

Conference Call Participants

Yasmeen Rahimi - Piper Sandler

Michael Yee - Jefferies

Josh Schimmer - Evercore ISI

Tiago Fauth - Credit Suisse

Sam Slutsky - LifeSci Capital

Jeff Jones - Oppenheimer

Operator

Thank you for standing by and welcome to the Ventyx Biosciences' Second Quarter 2022 Earnings Conference Call. At this time all participants are in listen only mode. After the speaker's presentation there will be a question-and-answer session. [Operator Instructions] As a reminder, today's program may be recorded.

And now, I'd like to introduce your host for today's program, Marty Auster, Chief Financial Officer, please go ahead, sir.

Marty Auster

Thank you, Jonathan. Good afternoon, everybody. Thanks for joining the call today. Welcome to Ventyx Biosciences' conference call webcast where we'll be discussing topline results from the Phase 1 trial of our TYK2 Inhibitor VTX-958. As a reminder, you can find press releases issued today covering the Phase 1 results from VTX-958 as well as our second quarter financial results on our website at ventyxbio.com under the Investor tab of the News & Events section.

Before we begin today, I'd like to remind everyone that conference call webcast will take forward-looking statements including statements about the potential and positioning VTX-958 and related market opportunities, the timing of commencement enrollment and completion of clinical trials, the anticipated timing of release of clinical trial data and the expected timeframe for funding operations and current cash equivalents and marketable securities. These statements are subject to risks and uncertainties that could cause actual results to differ. And please note, that these forward-looking statements reflect our opinion only as the date of this call. Factors that can cause actual results or outcomes to differ materially from those expressed or implied by such forward-looking statements are discussed in greater detail in our filings with the SEC including a Form 10-Q for the second quarter of 2022, which we do expect to file this afternoon.

Today's call will feature a presentation hosted by our CEO, Dr. Raju Mohan; and our President and Chief Medical Officer, Dr. Bill Sandborn. Following the presentation, we will open the call to your questions and at that time through Zoom, Bill will also be joined by our Executive Chairperson, Sheila Gujrathi; and our Chief Business Officer, Chris Krueger. We're also joined today by a special guest Dr. James Krueger, in addition to serving on the Ventyx Scientific Advisory Board, Dr. James Krueger is the Director of the Milstein Medical Research Program; and the D. Martin Carter, Professor in Clinical Investigation at Rockefeller University in New York. Dr. Krueger is a Board-Certified Dermatologist and was recognized as a world-renowned research expert on the Pathophysiology and Treatment of Psoriasis.